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UGF is a small peptide present in the urines and tissues of patients with gynecologic cancers.
Published research (which, at present, mainly comes from our laboratory) on the general
application of UGF as a tumor marker, and on its use in the diagnosis of ovarian cancer, is
reviewed, and new studies on its use, alone and with CAI25, in the management ofpatients with
ovarian cancer, are presented. In 234 healthy women, 89 with benign disease, and 79 with ovarian
cancer, UGF levels were above 3 fmol/ml (low cut-off) in 12 percent, 7 percent, and 82 percent,
respectively, and above 8 fmol/ml (high cut-off) in 1.7 percent, <1.1 percent, and 59 percent,
respectively. Similarly, 11 percent, 14 percent, and 70 percent, respectively, had CA125 levels
above 35 U/ml (low cut-off), and <1.9 percent, 1.2 percent, and49 percent had levelsabove a 200
U/ml (high cut-off). Ideally, the higher UGF and CA125 cut-offs should be used for diagnostic
applications, like differentiation of a benign from a malignant pelvic mass (false-positive rate:
UGF, <1.1 percent; CA125, 1.2 percent), but raising the cut-offs diminishes sensitivities for
malignancy (UGF, 59 percent; CA125, 49 percent). Thepopulationsdetected bythe twomarkers
only partially overlap, however, so that, together, UGF or CA125 can identify 75 percent of
malignant pelvic masses. Levels ofUGF (cut-off, >3 fmol/ml) and CA125 (35 U/ml) were also
monitored in 30 women undergoing therapy for ovarian cancer. Clinical observations were
reflected at each clinic visit by UGF alone in 67 percent, by CA125 alone in 57 percent, and by
UGF and CA125 together in 87 percent of cases. While separately UGF and CA125 levels
predicted 71 percent and 57 percent, together they forecast 86 percent ofrecurrent cancers prior
to clinical manifestations. UGF and CA125 should be used together in the detection and
management ofovarian cancers.
BACKGROUND
Human chorionic gonadotropin (HCG) is a glycoprotein hormone composed of a
common a-subunit (also found in lutropin, follitropin, and thyrotropin) and a unique
fl-subunit, which gives the molecule its luteotropic function. HCG is produced by
trophoblast tissue and can bedetected in theblood and urineofwomen with pregnancy
or trophoblast disease. Free HCG a- and fl-subunits are also present in blood and urine
ofwomen with pregnancy or trophoblast disease, at levels <1 percent to 40 percent of
that ofthe hormone [1-12].
HCG and HCG free subunit immunoreactivities have also been detected in the
serum and tissues of cancer patients [7,13-22]. Recently, Hussa [7] compiled the
results of 38 separate studies of HCG detection in cancer patients. As compiled
(n = 4,291, with testicular and trophoblastic cancers excluded), 19 percent ofsubjects
with cancer had detectable serum HCG levels. We analyzed 65 serum samples from
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women with active ovarian, cervical, and endometrial cancers. Consistent with the
compilation of Hussa [7], only 12 (18 percent) had detectable HCG levels [21].
Furthermore, the levels in the 12 HCG-positive samples (mean = 3.0 mlU/ml) were
close to the limit of detection (2 mlU/ml), restricting the range of HCG levels that
could be used for monitoring cancer therapy. We concurred with Hussa [7] and
concluded that HCG was not a useful marker ofnon-trophoblastic gynecologic cancers
and that other markers with higher cancer sensitivity were needed.
In 1977, Good and colleagues [5], demonstrated, using gel filtration techniques, that
a small form of HCG fl-subunit was present in pregnancy urines at levels higher than
that of HCG. During the following ten years, similar findings were observed by several
other researchers [23-29]. Chromatographic studies, and experiments with antibodies
directed to different sites on HCG, indicated that this small molecule was composed of
segments of f-subunit. As such, the term urinary HCG fl-subunit core fragment was
coined for this small molecule. In 1987-8, several laboratories generated antibodies
against HCG f-subunit core fragment and established specific immunoassays. Akar
and collaborators at N.I.H. generated fl-subunit core fragment antisera [30].
Krichevsky and colleagues at Columbia University generated a fl-subunit core
fragment-specific monoclonal antibody [31] (antibody B204), as did Kardana and
colleagues in London, England [32]. Using these antibodies in immunoassays, levels of
HCG,-subunit core fragment were determined in pregnancy and trophoblast disease
patient urines. In pregnancy urines, levels of f-subunit core fragment were shown to
exceed HCG levels, by two-(first trimester) to seven-(second trimester)fold. Similarly,
f-subunit core fragment levels in patients with trophoblast disease exceeded HCG
levels, by as much as fiftyfold [22,30,33,34].
The gel filtration studies by Good and colleagues in 1977 also showed that the small
fl-subunit fragment was present in placental tissue [5]. Recent studies by Kardana and
collaborators have confirmed these observations, by demonstrating that syncytiotro-
phoblast cells can be specifically stained for HCG f-subunit core fragment with
monoclonal antibody 2C2 [34]. Studies in our laboratory have shown that human
trophoblast organ cultures (n = 10), from first, second, or third trimester pregnancies
secrete HCG fl-subunit core fragment at levels similar to or exceeding those of HCG
[33]. Studies by Wehmann and Nisula [27] have, however, shown that when HCG
fl-subunit is administered to humans, f-subunit alone is detected in serum, but both
fl-subunit and fl-subunit core fragment can be detected in urines. This result suggested
the presence of an additional pathway for generating HCG fl-subunit core fragment,
possibly involving renal degradation of molecules.
Recently, our laboratory collaborated with that of Steven Birken at Columbia
University and determined the fine peptide and carbohydrate structure of HCG
f-subunit core fragment. As was shown [26], fl-subunit core fragment is composed of
HCG f-subunit residues 6-40 attached by four disulfide linkages to HCG f-subunit
residues 55-92, with two attached N-linked sugar units. The N-linked sugar units
lacked the sialic residues that are found on HCG oligosaccharides. The molecular
weight of HCG f-subunit core fragment was just 10,300, or 28 percent of that of HCG
(36,700). Recently, Wehmann and colleagues [35] showed that HCG f-subunit core
fragment is cleared from the circulation in humans 120 times faster than HCG (if
equal amounts were produced, circulating fl-subunit core fragment levels would be 0.8
percent ofthose of HCG). The rapid clearance rate is not surprising, when the absence
of sialic acid (which maintains the circulatory half-life of the glycoprotein hormones
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[20]) on HCG 3-subunit core fragment and the small size, relative to HCG, are
considered. The rapid clearance rate mayexplain whyfl-subunit core fragment is more
readily detected in urine than in serum samples (serum concentration is 70 times lower
than that in urine [36]).
Kardana and colleagues [34] used antibodies 2C2, INN13 (hCG-specific), and lE5
(free,B-subunit-specific), with histochemical methods, to stain fixed slices of non-
trophoblastic cancer tissues. While none of 83 tissue slices was stained with the HCG
or the free fl-subunit antibodies, 77 (93 percent) were stained with the fragment-
specific antibody, 2C2, at a distinctly higher level than surrounding control tissue.
Consistent with these findings, our laboratory has used immunoassays with antibodies
B204, 1E5, and B109 (HCG-specific) and gel filtration methods to indicate the
absence of HCG and free fl-subunit, and presence ofHCG fl-subunit core fragment in
five of five tissue pieces from ovarian cancer [20,36]. Other researchers have used
chromatographic methods [24-26,37] or, in more recent studies, immunoassays with
monoclonal antibodies 2C2 or B204 [21,22,34,38-41], to show that HCG fl-subunit
core fragment-like molecules are present in the urines of as many as 92 percent of
cancer patients. The finding that HCG f-subunit core fragment is produced by cancer
cells, in the absence of detectable HCG or fl-subunit, indicated a detachment in their
production. As such, the terms HCG and HCG f-subunit core fragment were
detached, and the latter called urinary gonadotropin fragment (UGF) [21,34,38-41].
In the past two years, we have published several articles on UGF assays, and on
applications of UGF and of UGF and CA125 measurements in the diagnosis of
gynecologic cancers [21,38-41]. This article reviews our published data and supple-
ments it with new observations on the use ofUGF alone, and ofUGF with CA125, in
the management ofovarian cancer and on the early detection ofrecurrent disease.
DEVELOPMENT OF UGF ASSAY
A specific immunoradiometric assay was developed for UGF. Urine, 200 ,zl, was
added to tubes coated with 900 ng monoclonal antibody B204. UGF was bound by the
coated tube, and urine removed. Radiolabeled monoclonal antibody HCO514
(directed to a common fl-subunit epitope) was then added, which labeled the bound
UGF. After removing excess labeled antibody, radioactivity was determined. A linear
relationship was found between UGFin urineand radioactivity. Thecross-reactivity of
HCG in this assay was <0.2 percent; with HCG freef-subunit, was 7.5 ± 0.54 percent;
and with lutropin or lutropin freef-subunit, was <0.1 percent. Overa six-month period
the intra-assay and inter-assay coefficients ofvariation averaged 7.8 ± 1.9 percent and
12.7 ± 1.7 percent, respectively, and the sensitivity (concentration different from 0
fmol/ml standard in Student's t-test) averaged 2.1 ± 0.31 fmol/ml. Details of these
methods, and of the effects of varying antibody concentrations and incubation
conditions, are published elsewhere [40].
ESTABLISHMENT OF CANCER SENSITIVITY AND SPECIFICITY,
AND CUT-OFF LEVELS
UGF levels were measured in 323 control samples, from 234 healthy women, and
from 89 with benign disease (Table 1). Thirty-three of the 323 women providing
control urines had UGF levels which exceed 3 fmol/ml; only four, however, exceed 8
fmol/ml, or 4 standard deviations among the mean. A cut-off of 8 fmol/ml was
indicated for screening-type applications, where a low false-positive rate (1.2 percent)
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TABLE 1
Incidence of False-Positive UGF Levels in Healthy Individuals, and Women with Benign Disease
Number of False-Positives
Number of
Patients >3 fmol/ml >8 fmol/ml
Healthy women
Pre-menopause 94 3 (3.2%) 0
Post-menopause 140 24 (17%) 4 (2.9%)
Subtotal 234 27 (12%) 4 (1.7%)
Women with benign disease
Endometriosis 16 3 (18%) 0
Ovarian neoplasm 14 0 0
Leiomyomata uteri 13 1 (8%) 0
Condyloma 15 0 0
Other 31 2 (6%) 0
Subtotal 89 6(7%) 0
Total 323 33 (10%) 4 (1.2%)
is critical. The higher false-positive rate, using the 3 fmol/ml cut-off (10 percent), is
lower than that reported for CA125 (14 percent and 35 U/ml cut-off [41,42]) and is
appropriate for application where sensitivity is less critical, such as monitoring the
progress ofpatients with established cancer.
Similar false-positive results were observed for two groups with similar age
distribution, women pre-menopause with no history of disease (0 of 94 exceed 8
fmol/ml) and women with benign gynecologic lesions (0 of89 exceed 8 fmol/ml). The
similarity of the results between these two groups indicates that benign pelvic lesions
such as endometriosis, benign ovarian neoplasm, and leiomyomata uteri do not falsely
elevate UGF levels. False-positive results were higher among women who were
post-menopause than pre-menopause (false-positive rates 2.9 percent and <1.1
percent, respectively, at 8 fmol/ml cut-off). Recent studies have shown that some
healthy post-menopausal women have low levels of HCG (0-10 mlU/ml) and HCG
free a- and free :-subunits in their circulation, of pituitary origin [43,44]. We
postulate that the 2.9 percent ofpost-menopausal women who have false-positive UGF
levels in urine are those whose pituitary produces cross-reacting HCG free,-subunit.
UGF levels were examined in 156 women with proven gynecologic cancers (Table
2). While UGF levels in 102 patient samples (65 percent), exceed 3 fmol/ml, only 70
(45 percent) exceed the 8 fmol/ml cut-off. The mean UGF level in cancer patients was
44 fmol/ml, the range of levels was 3-714 fmol/ml (240-fold different), which is
TABLE 2
Incidence of True Positive UGF Levels in Individuals with Gynecologic Cancer
Number ofTrue Positives
Number of
Patients >3 fmol/ml >8 fmol/ml
Ovary 71 58 (82%) 42 (59%)
Endometrium 33 20 (61%) 12 (36%)
Cervix 52 24 (46%) 16 (31%)
Total 156 102 (65%) 70 (45%)
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TABLE 3
Detection of UGF and CA125 Levels in Parallel Urine and Plasma Samples from Healthy
Individuals, and from Those with Benign and Malignant Pelvic Masses
UGF CA125 UGForCA125
Number of >3 >8 fmol/ml
Patients >3 >8 fmol/ml 35 200 U/ml 35 200 U/ml
Healthy women 234a 12% 1.7% 11% 0 (<1.9%)
Women with benign pelvic 443b 9.3% 0 (<2.3%) 14% 1.2%
mass (myoma, ovarian
cyst, or endometrioma)
Patients with malignant 71 82% 59% 70% 49% 96% 75%
pelvic mass, pre-surgery
or at initial clinic visit
Serous carcinoma 43 81% 60% 79% 56% 95% 79%
Endometrioid, mucinous, or 28 82% 57% 57% 39% 96% 68%
other ovarian carcinoma
'Only 53 plasma samples collected for CA125 measurements
bOnly 43 urine samples collected for UGF measurements
similar to that of CA125 (35-9,000 U/ml, 260-fold different [45]). The organ
specificity of UGF, as a cancer marker, was also similar to that of CA125 (Table 2).
While 82 percent, 61 percent, and 46 percent of ovarian, endometrial, and cervical
cancers, respectively, were detected by UGF (cut-off >3 fmol/ml), 76 percent, 59
percent, and 18 percent were reported to be detected by CA125 (cut-off 35 U/ml
[45]); however, the tissue specificities of UGF and CA125 for ovarian cancers were
markedly different. While UGF is impartial and detected a similar proportion of
serous (81 percent) and endometrioid/mucinous/other (82 percent) ovarian cancers
(Table 3), CA125 had a distinct preference for detecting serous malignancies
(sensitivity 79 percent, vs. 57 percent for other ovarian malignancies). We conclude
that UGF is a marker ofgynecologic cancers. Like CA125, UGF levels preferentially
mark ovarian malignancies. The sensitivity and specificity ofUGF (81 percent and 10
percent, cut-off>3 fmol/ml) and CA125 (79 percent and 14 percent, cut-off35 U/ml)
are similar for serous ovarian cancers. While CAl25 has reduced sensitivity for other
types of ovarian cancer, however, the sensitivity of UGF remains the same (82
percent).
APPLICATION 1: IN DIFFERENTIATING BENIGN AND MALIGNANT
PELVIC MASSES
The distinction of a benign from a malignant pelvic mass is a difficult problem for
the gynecologist. Physical examination may be of little use, and ultrasound, while
distinguishing an adnexal mass from a uterine mass, has limited use indifferentiating a
benign pelvic mass from a malignancy [46-49]. Tumor markers, such as CA125, are
also insufficiently accurate to help in the differential diagnosis of benign and
malignant disease. In studies at Yale-New Haven Hospital (Table 3), CAl25 detected
79 percent ofserous malignancies, but also detected 14 percent ofpatients with benign
pelvic masses. Studi-es at other centers show that CA125 detects 76 percent to 91
percent ofserous malignancies, but also 6 percent to 40 percent ofbenign pelvic lesions
[42,50-52].
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New methods are needed to distinguish masses and to identify malignancies
pre-operatively. With these methods, appropriate additional studies could be arranged
which may influence the typeofsurgery scheduled. Ifa malignancy is expected, then a
bowel prep and the necessary surgical expertise can be scheduled pre-operatively. In
this way, accurate staging procedures and complete tumor removal can be done, both
of which are very important for selection of the appropriate post-operative manage-
ment program.
We investigated the levels of UGF in patients with pelvic masses and its ability to
complement CA125 results. As shown inTable 3, UGFat a cut-offof>3 fmol/ml, like
CA125 at 35 U/ml, falsely detected a high proportion (9.3 percent and 14 percent,
respectively) of benign pelvic masses. When the UGF and CA125 cut-off levels were
raised to >8 fmol/ml and to 200 U/ml, respectively, the number of benign pelvic
masses detected was significantly reduced (to <2.3 percent and 1.2 percent, respec-
tively). The cancer sensitivities ofUGFand CA125 were reduced also (59 percent and
49 percent, respectively). The populations detected by the two markers only partially
overlap, however, so that, together, UGF or CAI25 can identify 79 percent of serous
and 68 percent ofother malignant pelvic masses.
The latter finding indicated new procedures for theevaluation ofpatients presenting
with a pelvic mass. Aurinespecimen should becollected for UGF measurementsand a
parallel plasma sample collected for CAI25. Using two assay results, with UGF at a
cut-offof >8 fmol/ml and CAl25 at acut-offof200U/ml, 75 percentofmalignancies
should be detected. The false-positive rate is 1.2 percent for CA125 alone, <2.3
percent for UGF alone, and <1.2 percent when, as in the majority ofcases, UGF and
CA125 are detected. These false-positive rates may be low enough for use in the
evaluation of pelvic masses. If elevated levels are detected (>8 fmol/ml or .200
U/ml), cancer should be assumed and appropriate measures taken.
APPLICATION 2: IN MONITORING THE THERAPY
OF OVARIAN CANCER
The clinical evaluation of tumor burden in ovarian cancer patients undergoing
therapy and follow-up is problematic. Currently, second-look surgical procedures are
commonly used to determine whether therapy should be halted or modified, or new
procedures instituted. The discovery of sensitive tumor markers which accurately
reflect the tumor burden may help to monitor clinical status better, alleviate the
necessity ofsecond-looksurgery, and possibly permitthedetection ofrecurrentdisease
prior to the appearance ofclinical signs, when therapy may be too late to be ofvalue.
CA125 is found in the plasma ofa high proportion ofpatients (reports vary from 76
percent to 91 percent) with serous ovarian cancers [42,50-52]. Several centers have
examined the use of plasma CA125 measurements in monitoring therapy of ovarian
cancer. Early reports showed that CAl25 levels diminished and became undetectable
as ovarian cancer patients responded to treatment [53-55]. This finding suggested that
CA125 levels reflected tumor burden, and applications for CA125 in monitoring the
efficacy oftherapy and in theearlydetection ofrecurrentdisease [53-55]. More recent
studies have found limitations in the useofCAl25 in ovarian cancer management. For
instance, reports indicate that >40 percent of patients who are clinically free of
disease, with CA125 levels (<35 U/ml) in the normal range, have persistent cancer
when evaluated by second-look surgery procedures [45,56,57]. Furthermore, it has
been suggested that diminishing CA125 levels in ovarian cancer patients do not
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TABLE 4
Detection of UGF and CA125 Levels in Parallel Urine and Plasma Samples from Patients with
Malignant Pelvic Masses: Breakdown by Stage (F.I.G.O.)
UGF CA125
Number of
Patients >3 >8 fmol/ml 35 200 U/ml
Stages I and II 5 80% 40% 40% 0
Stage III 40 75% 50% 60% 43%
Stage IV 10 100% 70% 90% 60%
Stage X 4 100% 100% 100% 100%
Recurrence 12 83% 75% 92% 67%
Total 71 82% 59% 70% 49%
necessarily indicate diminishing disease [58]. Additional markers are needed to back
up CA125 and to detect non-serous ovarian malignancies.
As described earlier, UGF is also produced by a high proportion of serous ovarian
carcinomas. In our experience (Table 3), CAI25 (cut-off, 35 U/ml) detects in plasma
79 percent, and UGF (cut-off, >3 fmol/ml) in urine a similar proportion (81 percent)
ofserous cystadenocarcinomas. LikeCA125, UGFsensitivity, and levels [41], increase
with advancing stage (Table 4). This finding suggests that UGF levels, like those of
CA125, may reflect tumor burden. UGF, however, unlike CA125, similarly detects
serous, mucinous, and endometrioid malignancies and, as described earlier, comple-
ments CA125 detection of serous cystadenocarcinoma (Table 3: UGF, 81 percent;
CAl25, 79 percent, and together they detect 95 percent ofserous cancers). The use of
UGF alone, and of UGF and CA125, was investigated, in following the therapy of
patients with ovarian cancer.
Levels of UGF and CA125 were monitored in 30 women undergoing therapy for
ovarian cancer. Twenty-one of the group (70 percent) had true positive UGF (>3
fmol/ml) and 19 ofthegroup (63 percent) had true positive CA125 levels (.35 U/ml)
at entry into the study or when cancer became clinically evident. Levels of UGF
accurately (at each clinic visit) reflected clinical observations during therapy in 20 of
the 21 (95 percent) true positives, or 67 percent of the 30 patients (Table 5). CA125
levels reflected clinical observations in 17 of the 19 (89 percent) true positives, or 57
percent of the 30 patients. Interestingly, UGF levels reflected the clinical course in a
similar proportion of the 19 CA125 true positives (64 percent) and 11 CA125 true
negatives (68 percent), suggesting the independence ofthetwo markers. While CA125
levels were most useful in monitoring patients with serous cancers (levels were
concordant with clinical observations in 67 percent of women with serous and 33
percent of those with other ovarian malignancies), UGF levels were best in the
management of those with endometrioid and other ovarian malignancies (levels
reflected clinical observations in 62 percent of those with serous and 77 percent of
patients with other cancers). These results further indicate that the two markers
complement each other, and the appropriateness of using them together, to back up
each other's false-negatives. Using UGF and CA125 together, therapy was appropri-
ately monitored at each clinic visit in 26 ofthe 30 (87 percent) patients.
We investigated the use ofUGF alone, CAl25 alone, and the two markers together
in the early detection of recurrent disease. Rising UGF and rising CA125 levels each
separately predicted four of seven recurrences in patients clinically free of disease.
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Using either marker, however, seven of seven recurrences were detected when first
clinically evident, and six ofseven at a clinic visit prior to that.
We conclude that UGF is a good back-up marker for CA125 and that it should be
used in monitoring all patients withovariancancer. Formucinous andother non-serous
ovarian cancers, UGFshould bethe markerofchoice, and, forserous malignancies, the
use of both UGF and CA125 is recommended. In our experience while following the
progress of 21 patients with serous cancer, changes in CA125 and UGF levels do not
conflict with each other, so that, in patients clinically free of disease, an elevation of
either CA125 or UGF indicates a recurrence, and the need to start appropriate
therapy.
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